IL6R and arthritic joint disease: The improvement in arthritis scores by IA PLGA‐ATRA MP is superior to the reported efficacy of methotrexate in SKG mice, a first line DMARD, even though it is administered at a dose (1 mg kg−1 daily) which is ≈20‐fold greater than the typical clinically used dose of methotrexate in humans.[46] The efficacy of IA PLGA‐ATRA MP was comparable to weekly systemic administration of 100 μg anti‐IL‐17A antibody treatment in SKG mice or weekly systemic administration of 200 μg anti‐IL‐6R.[22]